| Popis: |
Background & objectives: Cutaneous leishmaniasis is an infection caused by protozoan genus Leishmania. Althoughglucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liverenzymes and electrocardiogram changes. In addition, the drug is expensive, the injection is painful, and researchshows that resistance of parasite to glucantime is growing in different parts of the world. Therefore, scientists arepaying more attention to develop new drugs such as nanosilver solution. The present study is an attempt toevaluate the in vivo topical effects of different concentrations of nanosilver solution in the treatment of leishmaniasislesions.Methods: In all, 90 female Balb/c mice aged 6–8 wk were infected with 2×106 viable stationary-phase promastigotesin the base of tail. Different concentrations (60, 80, 120, 130 and 2000 ppm) nanosilver solution were used in thepresent study to test the efficacy in the treatment of lesions. Clinical control of the infection trends was conductedweekly for 5 wk by measuring lesion diameter with standard Kulis-Vernieh. Data were analyzed by paired t-test,analysis of variance (ANOVA), and Tukey test.Results: Mean lesion diameter pre- and post-treatment did not significantly differ between different treatmentgroups (p >0.05). Likewise, a significant difference in splenic parasite load was also not observed between differenttreatment groups.Interpretation & conclusion: Based on our results, different concentrations of nanosilver are ineffective in reducingmean sizes of lesions. |
